CROI 2013: Sofosbuvir + Ribavirin Works Well for Inner-City Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 March 2013 00:00
- Written by Liz Highleyman
A simple 24-week, all-oral regimen of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 chronic hepatitis C, many of whom had factors predictive of poor response, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: AbbVie Interferon-free Combos Cure Most Newly Treated Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 March 2013 00:00
- Written by Liz Highleyman
All-oral regimens containing the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor, and ribavirin led to sustained response for more than 90% of previously untreated patients -- including those with unfavorable IL28B gene patterns -- but only about half of prior non-responders, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: Consistent Condom Use Stops 70% of HIV Infections, Says CDC
- Details
- Category: HIV Prevention
- Published on Friday, 15 March 2013 00:00
- Written by Gus Cairns
An analysis by Dawn Smith of the U.S. Centers for Disease Control and Prevention (CDC) reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta has provided the first estimate of the efficacy of condoms in preventing HIV transmission during anal sex since 1989. It found that condoms stop 7 out of 10 anal transmissions -- the same efficacy found by the 1989 study.
CROI 2013: Gay Men More Aware of HIV Status, Black Men Remain 'Over-burdened' [VIDEO]
- Details
- Category: HIV/AIDS Epidemiology & Mortality
- Published on Friday, 15 March 2013 00:00
- Written by Gregory Fowler
A growing number of men who have sex with men in the U.S. are aware that they have HIV, but prevalence appears to be stable, according to an analysis of National HIV Behavioral Surveillance data presented by researchers from the Centers for Disease Control and Prevention (CDC) at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: MK-1439 -- A Novel NNRTI For HIV Treatment [VIDEO]
- Details
- Category: HIV Treatment
- Published on Friday, 15 March 2013 00:00
- Written by Gregory Fowler
A next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), MK-1439, demonstrated good antiretroviral activity and tolerability as 7-day monotherapy in a small Phase 1b trial, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
More Articles...
- CROI 2013: Challenges and Opportunities for the Development of Long-acting Antiretrovirals [VIDEO]
- Presidio and Boehringer Ingelheim Will Collaborate on Interferon-free Hepatitis C Combo
- CROI 2013: Adding Telaprevir Increases Acute Hepatitis C Cure Rate for HIV+ Men
- CROI 2013: Simeprevir and Faldaprevir Boost Interferon Response Rates for HIV/HCV Coinfected
Web Design and Development by